Price at ~1,834 is 8.1% above rising 200 SMA (1,696), confirming long-term uptrend.
$11.75B all-cash deal for Organon at $14/share.
All-cash Organon deal valued at ~$7B, stock surged 120% in April.
Revenue CAGR 10.6% over 4 years; net income up 3.3x since FY2022.
$11.75B Organon acquisition is largest overseas deal in Indian pharma history.
Stock rallied 14% in 9 sessions on 10x volume, signaling exhaustion.
RSI at 65.71 is bullish, not overbought; golden cross confirms uptrend strength.
14% rally in 9 sessions on 10x volume signals exhaustion risk.